证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－054 公司董事会对姚东晗女士担任副总裁职务期间的工作表示感谢！ 特此公告。 华润双鹤药业股份有限公司(以下简称"公司")董事会近日收到公 司党委副书记、副总裁姚东晗女士提交的书面辞职报告，因工作安排 原因，其申请辞去副总裁职务，辞职申请自送达董事会之日起生效。 后续姚东晗女士将担任公司党委专职副书记。 | 姓名 | 离任职 | 离任时间 | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 务 | | | 到期日 | | | 股子公司任职 | | 毕的公开 | | | | | | | | | | | 承诺 | | 姚东晗 | 副总裁 | 2025 年 | 6 | 2027 7 | 年 | 工作安排 | 是 | 党委专职 | 否 | | | | 月 24 | 日 | 月 10 | 日 | | | 副书记 | | 一、提前离任的基本情况 二、离任对公司的影响 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－053 华润双鹤药业股份有限公司 关于通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")收到北京 市药品监督管理局颁发的《药品 GMP 符合性检查告知书》(京药监药 GMP[2025]020024)，现将相关情况公告如下： 一、GMP 检查相关信息 结论：根据本次检查情况，经审查，该企业此次检查范围符合《药 品生产质量管理规范(2010 年修订)》和附录要求。 本次检查为新建综合制造车间一层固体制剂生产线、软袋输液车 间冲洗剂 Q 线药品 GMP 符合性检查合并开展巯嘌呤片(Ⅱ)上市前药 品 GMP 符合性检查。前述生产线的投入为人民币 1,033.10 万元(未经 审计)。 被检查单位名称：华润双鹤药业股份有限公司 检查地址：北京市朝阳区双桥东路 2 号 检查范围及相关车间、生产线： ①综合制造车间一层固体制剂生产线[检查品种巯嘌呤片(Ⅱ)(国 药准字 H20250006)] ②软 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－052 华润双鹤药业股份有限公司 关于控股子公司湖南省湘中制药有限公司 氢溴酸伏硫西汀片获得药品注册证书的公告 氢溴酸伏硫西汀片由丹麦灵北制药(H.Lundbeck A/S)和日本武田 制药(Takeda)联合研发，于 2013 年 9 月 30 日获得批准在美国上市， 2017 年 11 月 21 日原研进口产品获得批准在中国上市，商品名为 "Trintellix"。根据全球 71 国家药品销售数据库显示，2023 年氢溴 酸伏硫西汀片全球销售额为 19.99 亿美元，其中"Trintellix"的销售 额为 12.93 亿美元。 近日，华润双鹤药业股份有限公司(以下简称"公司")控股子公司 湖南省湘中制药有限公司(以下简称"湘中制药")收到了国家药品监督 管理局(以下简称"国家药监局")颁发的氢溴酸伏硫西汀片(以下简称 "该药品")《药品注册证书》(编号：2025S01584)。现将相关情况公告 如下： | ...

Group 1 - The core point of the article is that China Resources Double Crane (华润双鹤) announced that its subsidiary, Xiangzhong Pharmaceutical, received a drug registration certificate from the National Medical Products Administration for Hydrobromide Vortioxetine Tablets, which are used to treat adult depression [1] - The drug has been under development since 2021 and is expected to be approved for market launch by May 27, 2025 [1] - The total research and development investment for the drug has reached 12.1484 million yuan [1] Group 2 - In 2023, the global sales revenue for the drug reached 1.999 billion USD, while the domestic market sales totaled 214 million yuan [1]

Group 1 - The Artemisinin concept sector rose by 1.17%, ranking 7th among concept sectors, with six stocks increasing in value, including Fosun Pharma, Zhejiang Medicine, and Haizheng Pharmaceutical, which rose by 5.23%, 4.94%, and 1.54% respectively [1] - The leading stocks in terms of net inflow of main funds were Zhejiang Medicine, Fosun Pharma, Baiyun Mountain, and Haizheng Pharmaceutical, with net inflows of 856.29 million, 545.22 million, 103.85 million, and 52.54 million respectively [1] - The main fund inflow rates for Zhejiang Medicine, Baiyun Mountain, and Fosun Pharma were 7.58%, 7.56%, and 3.62% respectively [2] Group 2 - The top gainers in the concept sector included pork, chicken farming, innovative drugs, and animal vaccines, while the top losers included controllable nuclear fusion and decelerators [1] - The overall market performance showed a mixed trend, with some sectors experiencing significant gains while others faced declines [1] - The trading volume and turnover rates varied among the stocks, indicating differing levels of investor interest and activity [2][3]

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－051 华润双鹤药业股份有限公司 关于全资子公司安徽双鹤药业有限责任公司 通过 GMP 符合性检查的公告 被检查单位名称：安徽双鹤药业有限责任公司 检查地址：安徽省芜湖市三山经济开发区天成路 2 号 检查范围及相关车间、生产线： | 检查范围 | 车间 | 生产线 | | --- | --- | --- | | 小容量注射剂 | 三车间 | 线 H | | 大容量注射剂(直立式聚丙烯 | | | | 输液袋)[碳酸氢钠林格注射 | 五车间 | 线 V | | 液(国药准字 H20249422)] | | | 检查时间：2025 年 2 月 25 日至 2 月 28 日 结论：符合要求 本次检查为新建三车间 H 线药品 GMP 符合性检查合并开展碳酸 氢钠林格注射液上市前药品 GMP 符合性检查。前述生产线的投入为 人民币 1,029.51 万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 安 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-050 华润双鹤药业股份有限公司 关于全资子公司华润紫竹药业有限公司 地诺孕素片获得俄罗斯药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 截至本公告日，公司就该药品在俄罗斯注册的研发投入为18.90 万元人民币(未经审计)。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 华润紫竹药业有限公司(以下简称"华润紫竹")收到了俄罗斯联邦卫生 部颁发的地诺孕素片(以下简称"该药品")的《药品注册证书》[编号： ЛП-№(009788)-(РГ-RU)]。现将相关情况公告如下： | 药品商品名 | ® Эндомеклин | | --- | --- | | 活性成分的化学名称 | 地诺孕素 | | 剂型 | 片剂 | | 规格 | 2mg | | 生产商名称 | 华润紫竹药业有限公司 | | 生产地址 | 中国北京市朝阳区朝阳北路 号 27 | 一、批件主要内容 兹确认：该药品在俄罗斯联邦(欧亚经济联盟成员国)境内完成注 册并获批 ...

华润双鹤公告，全资子公司 华润紫竹药业有限公司的地诺孕素片获得俄罗斯联邦卫生部颁发的《药品 注册证书》。该药品用于治疗子宫内膜异位症，华润紫竹于2022年9月启动注册工作，2024年3月提交上 市许可申请并获批。截至公告日，研发投入为18.9万元人民币。2023年，地诺孕素片全球销售额为3.65 亿美元。2024年，国内销售总额为7.9亿元人民币，其中Jenapharm市场份额为87.18%，上海汇伦江苏药 业为9.32%。2024年，公司该药品销售收入为4,276.49万元，在俄罗斯尚未形成销售。 ...

Group 1 - The core viewpoint of the article highlights the decline of the artemisinin concept sector, which fell by 0.82%, ranking among the top declines in the concept sector [1][2] - Within the artemisinin concept sector, major companies such as Rundu Co., Zhejiang Medicine, and Kunming Pharmaceutical experienced significant declines, while only two stocks, Delong Huineng and Baiyunshan, saw increases of 1.06% and 0.37% respectively [1][2] - The article provides a detailed overview of the capital flow, indicating a net outflow of 58 million yuan from the artemisinin concept sector, with Rundu Co. leading the outflow at 43.43 million yuan [2] Group 2 - The article lists the top-performing concept sectors, with the military equipment restructuring concept leading with a gain of 3.92%, while the artemisinin concept was among the worst performers [2] - A table is provided showing the capital flow for various companies within the artemisinin concept, detailing their respective price changes and turnover rates, with Rundu Co. showing a significant outflow [2]